This article presents a subgroup analysis of the phase 3 SOLSTICE clinical trial, focusing on solid organ transplant recipients treated with maribavir for refractory cytomegalovirus (CMV) infection. The study compared maribavir to investigator-assigned therapy, assessing efficacy in CMV viremia clearance and safety, including treatment-emergent adverse events and the development of maribavir resistance. Results showed maribavir's superiority in CMV clearance across various transplant types and fewer treatment discontinuations compared to standard treatments. The findings support maribavir's effectiveness and safety profile in this specific patient population. Limitations of the open-label design and sample size are acknowledged.

PMID: 39613120

Blumberg EA, Witzke O, Harber M, et al. Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: Subgroup analysis of the phase 3 randomized SOLSTICE study. J Heart Lung Transplant 2024;S1053-2498(24)01971-5.

Created with NotebookLM by Google so there may be mistakes and/or errors.

This study, published in Bone Marrow Transplantation, analyzes adenovirus (ADV) infections in children and adults after allogeneic hematopoietic cell transplantation (allo-HCT). Researchers examined 2529 patients from the EBMT database, identifying risk factors for mortality. Children demonstrated better short-term survival than adults, with different factors influencing mortality in each group. In children, pre-transplant factors like CMV serostatus and performance score were key, whereas in adults, factors directly related to ADV infection, such as the type of infection and time of onset, were more impactful. The study highlights the need for regular ADV screening in both children and adults post-allo-HCT.

Created with NotebookLM by Google so there may be mistakes and/or errors.

PMID: 38987308

Styczynski J, Tridello G, Knelange N, et al. Adenovirus infections after allogeneic hematopoietic cell transplantation in children and adults: a study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2024;59(10):1402–12.

This research article reports on a randomized clinical trial (BEATLE) investigating the efficacy of extended-infusion versus intermittent-infusion β-lactam antibiotics in treating febrile neutropenia in hematological patients. The study, conducted across four Spanish hospitals, aimed to determine if extended infusion improved treatment success, defined as defervescence without antibiotic changes. Results showed no significant difference in treatment success between the two groups. However, extended infusion achieved higher pharmacokinetic/pharmacodynamic targets for susceptible Pseudomonas aeruginosa. The authors conclude that extended infusion isn't routinely warranted but may benefit patients with infections caused by less susceptible microorganisms.

Created with NotebookLM by Google so there may be mistakes and/or errors.

PMID: 39433124

Laporte-Amargos J, Carmona-Torre F, Huguet M, et al. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial. Clin Microbiol Infect 2024;S1198-743X(24)00488-9.